Aurobindo Pharma subsidiary receives USFDA’s Establishment Inspection Report; stock rises over 4%

Madhu Balaji Updated - December 20, 2023 at 01:25 PM.

Aurobindo Pharma Ltd has informed the stock exchanges that the company’s wholly-owned subsidiary APL Healthcare Ltd. has received establishment inspection report (EIR) from the USFDA, classifying its manufacturing facility at Tirupati, Andhra Pradesh, as ‘voluntary action indicated’ (VAI).

The US FDA conducted an inspection at the company’s unit situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023.

Aurobindo Pharma stock traded at ₹1,076.90 on the NSE, up by 4.26 per cent as of 1:06 pm on Wednesday.

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW
Published on December 20, 2023 07:55
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles